Articles tagged with Pancreatic Cancer
Scientists at Huntsman Cancer Institute have discovered a way for cells to override genetic changes, potentially leading to more effective pancreatic cancer treatment. The study found that introducing PTF1A into normal cells prevented the formation of cancer cells and even reversed early-stage cancer cells back to healthy pancreas cells.
A phase 1 clinical trial found that combining AZD1775, a Wee1 inhibitor, with radiation and gemcitabine resulted in better-than-expected overall survival in patients with locally advanced pancreatic cancer. The median overall survival was 22 months, surpassing previous results for the same treatment combination.
Researchers found that pancreatic tumours produce more perlecan to remodel the environment, helping cancer cells spread and resist chemotherapy. Lowering perlecan levels improved response to treatment in mouse models.
Scientists have discovered a rare, inherited gene mutation that significantly increases the risk of pancreatic and other cancers. The RABL3 mutation was found in a family with multiple relatives diagnosed with pancreatic cancer, and zebrafish carrying the mutation also showed dramatically higher rates of cancer.
Researchers at Columbia University Irving Medical Center have identified a potential new therapy for pancreatic cancer. Their experimental compound, PTC596, has shown to be effective in combination with standard treatment, extending survival by three times in genetically engineered mice.
A new mouse model called KPP better mimics human cachexia symptoms, allowing researchers to control when cancer can be triggered. This advancement could lead to novel discoveries and identification of therapeutic targets for this devastating syndrome.
The USPSTF continues to recommend against routine screening for pancreatic cancer in asymptomatic adults due to its poor prognosis. This recommendation is based on the limited effectiveness and potential harms of screening in this population.
Two known gene mutations, KRAS and TP53, induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system. Mutations in these genes are closely linked to pancreatic ductal adenocarcinoma, a type of pancreatic cancer with a low five-year survival rate.
Researchers have identified a key protein involved in pancreatic cancer cell growth and found an antibody therapy that targets it, reducing tumour growth and increasing survival time in mice. The treatment combines the antibody with gemcitabine and achieves up to a sixfold increase in survival time compared to controls.
A nationwide study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that high blood sugar levels significantly increase the risk of pancreatic cancer. The study suggests that early detection of hyperglycemia and lifestyle modifications to improve glucose profiles may help lower this risk.
The Damon Runyon Cancer Research Foundation has awarded $3.5 million in fellowships to 15 early-career researchers, providing them with independence to pursue high-risk projects. The funding aims to support innovative cancer research and encourage promising young scientists to pursue careers in the field.
Researchers at Houston Methodist and MD Anderson Cancer Center have found a new immunotherapy to treat ovarian and pancreatic cancers by blocking the action of MFAP5 protein. This protein promotes tumor growth and reduces survival rates in patients with these cancers.
Researchers created a comprehensive test using machine learning algorithms to better guide patient management for pancreatic cysts, a precursor of pancreatic cancer. The test, called CompCyst, outperformed the current standard-of-care in an international study, avoiding surgery in 60% of patients who underwent unnecessary removal.
A new laboratory test using artificial intelligence tools has been shown to more accurately sort out which people with pancreatic cysts will go on to develop pancreatic cancers. The test, dubbed CompCyst, correctly identified patients who did not need surgery in over half of cases.
Researchers discover a novel compound that activates CD11b receptors on white blood cells, promoting an anti-tumor immune response and overcoming resistance to immunotherapies. This breakthrough may lead to new treatments for the third deadliest cancer in the US.
Researchers identified a compound that promotes a vigorous immune assault against pancreatic tumors, significantly shrinking them and improving survival. The compound, ADH-503, shifts the balance of myeloid cells toward those that activate T cells to attack cancer, making resistant cancers susceptible to immunotherapy.
Researchers at Cold Spring Harbor Laboratory discovered that pancreatic cancer cells destroy their own mitochondria to reduce reactive oxygen species and proliferate. Inhibiting the NIX pathway may prevent cancer cells from using energy to proliferate, offering a promising new target for therapies.
Researchers have identified a signaling pathway regulating macropinocytosis in pancreatic tumors, which could lead to personalized treatments. The study reveals that tumors can dynamically adjust their nutrient uptake, with some 'dialing up' or 'dialing down' macropinocytosis based on glutamine availability.
A widely recognized biomarker, CA19-9, is found to promote the development of pancreatic diseases and cancer in genetically engineered mice models. This discovery suggests new treatment strategies for pancreatic cancer and other cancer biomarkers.
Researchers discovered that CA19-9, a complex sugar molecule, causes pancreatitis by recruiting the immune system and inducing deleterious biochemical reactions. Targeting CA19-9 with antibodies may prevent or treat pancreatitis and its progression to pancreatic cancer.
Researchers found that FOLFIRINOX prolonged patients' lives by an average of 22.2 months, increasing the chances of complete tumor removal through surgery. More than two-thirds of cancers responded well to treatment, allowing for surgical removal.
Researchers have identified a new type of fibroblast in pancreatic cancer tumors that can evade immune detection. The discovery, published in Cancer Discovery, highlights the complex role of these cells in protecting cancer cells and could lead to new therapeutic strategies.
Researchers from the University of Oklahoma College of Medicine have identified ZIP4 as the trigger for muscle-wasting cachexia in pancreatic cancer. By inhibiting ZIP4, they hope to prevent cachexia and improve treatment outcomes for patients with pancreatic cancer.
A new pilot study demonstrated the feasibility of using molecular tumor markers to guide chemotherapy selection in patients with metastatic pancreatic cancer. The study reported promising progression-free survival and overall survival rates, with partial responses seen in 28% of patients.
Researchers have identified a biomarker that can accurately predict which pancreatic cysts are likely to become cancerous, offering new hope for improved diagnosis and treatment. The biomarker, mAb Das-1, was found to be more accurate than current methods in predicting cancer risk, with a accuracy rate of 95%.
A recent study by USC researchers found that Native Hawaiians have a 60% increased risk of pancreatic cancer compared to European Americans. The study also revealed that Japanese Americans and African Americans are at a higher risk than previously thought, with increases of 33% and 20%, respectively.
The POLO trial shows that olaparib significantly reduces the risk of disease progression or death in metastatic pancreatic cancer patients with BRCA mutations. Progression-free survival was 7.4 months on the olaparib arm, compared to 3.8 months on the placebo arm.
Researchers from Stand Up To Cancer will discuss their work on advancing immunotherapy for pediatric brain tumors, genome-wide cell-free DNA fragmentation profiling for early cancer detection, and personalized consolidation immunotherapy in localized non-small cell lung cancer. The findings highlight promising approaches to screening, ...
A study found that pancreatic cancer cells can behave differently based on their surroundings, with some responding better to chemotherapy and radiation. The stroma of tumors consists of connective tissue cells that contribute to tumor growth and spread.
Seven cutting-edge research projects have been awarded grants to tackle pancreatic cancer, with a focus on early diagnosis, potential new treatments, and understanding immunotherapy's limitations.
A new study found that one-third of patients with metastatic pancreatic cancer do not see a medical oncologist, and even more do not receive cancer-directed treatment. The data suggest that there are many missed opportunities for important discussions between patients and cancer specialists.
Eight researchers from the University of Texas M. D. Anderson Cancer Center have been awarded $100,000 fellowships to conduct high-impact cancer research over two years. The Andrew Sabin Family Fellowship Program aims to encourage creativity and innovation in cancer research.
Researchers found that removing the ATDC gene from pancreatic cells prevented the development of pancreatic cancer in mice. The study identified ATDC as a key player in the reprogramming of adult cells into primitive, high-growth cell types, which can lead to cancer.
In a mouse model of unresectable pancreatic cancer, administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival. The study found that FG-4592 effectively mimicked hypoxia in normal tissues, protecting them from radiation damage.
Researchers at Salk Institute uncover role of signaling protein LIF in pancreatic cancer development and progression, suggesting it may be a useful biomarker for earlier diagnosis and more effective therapies. Elevated LIF levels were significantly correlated with tumor cell status and response to chemotherapy.
Researchers found that the interaction between pancreatic stellate cells and cancer cells could be exploited due to high levels of LIF, a key protein responsible for activating PSCs in cancer cells. Elevated LIF levels correlate with disease progression and chemotherapy resistance.
A new diagnostic method for pancreatic cancer has been developed by researchers at the University of Copenhagen, utilizing circular DNA to identify cancer cells in blood tests. The technology is expected to classify cancer cells in individual patients and implement personalized treatment regimens, leading to increased survival rates.
Researchers from CNIO have successfully removed advanced pancreatic ductal adenocarcinoma (PDA) in animal models through combined inhibition of EGFR and c-RAF kinase. This breakthrough has shown significant promise for developing new cancer treatments.
Researchers have identified a key hormone receptor called RORγ that promotes tumor growth and is responsible for therapy resistance in pancreatic cancer. Blocking this receptor slows patient-derived tumor growth and improves survival in animal models, providing new avenues for research and potential therapies.
A Mayo Clinic study found that extended chemotherapy, a normal CA 19-9 tumor marker, and a dead tumor after surgery can significantly increase survival time for patients with advanced pancreatic cancer. The study achieved an average survival time of 58.8 months, or nearly five years.
Researchers found that rucaparib reduced tumor size and controlled growth in 17 out of 19 patients with BRCA1, BRCA2, or PALB2 mutations. The study provides promising early evidence for this approach as a less toxic option.
A subgroup of patients with advanced BRCA- or PALB2-mutated pancreatic cancer showed sustained clinical responses to rucaparib, a PARP inhibitor. The treatment provided complete or partial responses and reduced tumor size in some instances.
A study found that excess body weight before age 50 is strongly associated with an increased risk of dying from pancreatic cancer. The research, which analyzed data from over 963,000 adults, suggests that excess weight measured earlier in adulthood may be more closely linked to pancreatic cancer risk than previously thought.
A new combination of immunotherapy and chemotherapy has caused tumors to shrink in 83% of patients with metastatic pancreatic cancer. The treatment, involving a CD40 antibody, checkpoint inhibitor, and standard-of-care chemotherapy, showed manageable side effects, suggesting a durable response.
The Pancreatic Cancer Collective has awarded two million-dollar grants to AI teams developing tools to identify high-risk individuals with pancreatic cancer. One team will focus on rare gene variants and the other on machine learning analysis of clinical records and images.
African American women with poor oral health may face a substantially increased risk of developing pancreatic cancer. Researchers found that adult tooth loss and periodontal disease prevalence were associated with a higher risk, particularly among those who had lost at least five teeth.
A study published in Nature identified a new approach to starve pancreatic cancer cells of molecular resources. The researchers found that the protein syndecan-1 plays a critical role in regulating macropinocytosis, a mechanism used by cancer cells to scavenge resources and divide.
Research highlights the development of next-generation CAR T-cells and immune profiling to overcome tumor resistance. SU2C presents work on cancer interception, convergence, and clinical trials for pancreatic, pediatric, brain, colorectal, lung, ovarian, and breast cancers.
Researchers established two human pancreatic cancer cell sublines with high metastasis potential, MIA PaCa-2 In8 and Panc-1 In8, which demonstrated increased migration, invasion, and clonogenic abilities compared to their parental cells. The study also identified a dysregulated lncRNA-miRNA-mRNA competitive endogenous RNAs (ceRNAs) net...
Researchers found that tumor-associated macrophages release compounds that block the action of gemcitabine in malignant cells. The study suggests that patients with fewer macrophages in their tumors may respond better to chemotherapy. This discovery could lead to new approaches for treatment.
A recent study found that high levels of the 'proofreading' enzyme PHLPP1 lead to low PKC levels in pancreatic cancer patients, associated with poor prognosis. The researchers aim to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC to improve survival rates.
Researchers have identified a promising new therapeutic strategy using two types of drug inhibitors to treat pancreatic cancer. The approach combines chloroquine with an inhibitor of the replication stress response pathway, showing potential in reducing tumor growth and improving prognosis.
Researchers at GW Cancer Center discovered USP15 as a potential biomarker for treatments of breast and pancreatic cancers. The enzyme regulates homologous recombination repair and cancer cell response to PARP inhibitors.
Researchers found that oral bacteria are associated with the severity of cystic pancreatic tumours, which can become cancerous. The study suggests that certain oral bacteria may play a role in the development of pancreatic cancer.
Researchers at Huntsman Cancer Institute discovered a combination drug therapy that may effectively combat the disease. The study, led by Conan Kinsey and Martin McMahon, found a strong response in mouse models and may be a promising therapy for patients with pancreatic cancer.
Researchers have discovered a combination drug therapy that may effectively combat pancreatic cancer. The Pancreatic Cancer Collective, led by Martin McMahon and David Tuveson, has received funding to support clinical trials of the new treatment.
Researchers at UPMC and the University of Pittsburgh School of Medicine discovered genetic flags in 17% of tumors indicating susceptibility to existing chemotherapy drugs. The study's findings could lead to personalized treatment approaches for pancreatic cancer patients, increasing survival rates.
Researchers at UNC Lineberger Comprehensive Cancer Center have made a promising discovery in treating pancreatic cancer by making cells reliant on autophagy, a process of cellular recycling. A novel treatment strategy combining an autophagy inhibitor with another compound has shown increased efficacy in laboratory studies.
A retrospective study found that inherited mutations in pancreatic cancer susceptibility genes may increase the risk of developing pancreatic cancer in patients with specific precursor lesions. The study analyzed DNA from 315 patients and found a higher likelihood of invasive pancreatic cancer in those with inherited mutations.
Differential H3K27AC marks were identified at enhancer regions of genes including c-MYC, MED1, OCT-4, NANOG, and SOX2. Alteration in transcription and enhancer landscape occurs during disease progression, offering a potent therapeutic mark for targeting cancer cells.